A/Brisbane/10/2007 (H3N2)

NR-50437?? H3 Hemagglutinin (HA) Protein with C-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus(Proteins)|Influenza A virus|H3 Hemagglutinin (HA) Protein with C-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: H3 Hemagglutinin (HA) Protein with C-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus, NR-50437.”|Quantity limit per order for this item is 1. This item can be ordered twice a year.  Orders over this limit will be sent to NIAID for approval before shipment. This item is currently in our production queue. Please allow ample time for distribution lots to be made available. A recombinant form of the H3 hemagglutinin (HA) protein from influenza A virus, A/Brisbane/10/2007 (H3N2) containing a C-terminal histidine tag was produced in Sf9 insect cells using a baculovirus expression vector system and was purified by nickel affinity chromatography. The HA protein includes a C-terminal peptide containing a thrombin cleavage site, trimerizing (foldon) domain and eight histidine residues. The full-length HA precursor protein is 566 residues (GenPept: AIW60702). Note that NR-50437 does not exhibit hemagglutination activity. Each vial contains 50 ?g to 150 ?g of purified recombinant HA protein in PBS (pH 7.4).

NR-43784?? N2 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus(Proteins)|Influenza A virus|N2 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus|-20°C or colder|BEI ResourcesAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: N2 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus, NR-43784."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.A recombinant form of the N2 neuraminidase (NA) protein from influenza A virus, A/Brisbane/10/2007 (H3N2) containing an N-terminal histidine tag was produced in Sf9 insect cells using a baculovirus expression vector system and purified by nickel affinity chromatography. The predicted ectodomain coding region of the NA gene was fused to a synthetic gene segment encoding an N-terminal eight-histidine tag followed by a 43 amino acid tetramerization domain from vasodilator-stimulated phosphoprotein (VASP) and a thrombin cleavage site, as described for the 1918 pandemic virus. The full-length NA precursor protein is 469 residues (GenPept: AFN11835). Each vial contains approximately 200 ?g of purified recombinant NA protein in D-PBS (pH 7.4).NR-43784 was demonstrated to be functionally active based on its ability to cleave the fluorogenic substrate 2’-(4-methylumbelliferyl)-a-d-N-acetylneuraminic acid (4-MUNANA).

NR-19321??Influenza A Virus, A/Brisbane/10/2007 (H3N2), BPL-Inactivated (Antigen Preparations)|Influenza A virus|Influenza A Virus, A/Brisbane/10/2007 (H3N2), BPL-Inactivated|-70°C or colder|A KlimovAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Influenza A Virus, A/Brisbane/10/2007 (H3N2), BPL Inactivated, NR-19321."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval. This item is currently in our production queue. Please allow ample time for distribution lots to be made available. NR-19321 is a preparation of influenza A virus, A/Brisbane/10/2007 (H3N2) that has been inactivated with beta-propiolactone (BPL). A/Brisbane/10/2007 (H3N2)-like viruses were used as the influenza A (H3N2) component of trivalent vaccines worldwide from 2008 to 2010. The source virus used for the inactivation was BEI Resources NR-12283. Influenza A virus, A/Brisbane/10/2007 (H3N2) was isolated from a human in Brisbane, Australia on February 6, 2007. Sequence information is available for influenza A virus, A/Brisbane/10/2007 (H3N2) at the Influenza Research Database. Each vial contains approximately 5.0 x 10⁴ CEID₅₀ equivalents of BPL-inactivated influenza A virus, A/Brisbane/10/2007 (H3N2) in 100 ?L of PBS.